Cory Cashman, MD
Internal Medicine · Marrero, LANPI 1194739326
Payments from drug & device makers
Across 215 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$613
- Teva Pharmaceuticals USA, Inc.$558
- Bayer$472
- Amgen$453
- Lilly USA, LLC$299
- AbbVie$256
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,43295%
- Education$2315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $613 |
| Teva Pharmaceuticals USA, Inc. | 19 | $558 |
| Bayer | 13 | $472 |
| Amgen | 22 | $453 |
| Lilly USA, LLC | 17 | $299 |
| AbbVie(2 entities) | 21 | $256 |
| Otsuka America Pharmaceutical, Inc. | 12 | $230 |
| Merck | 13 | $227 |
| Novartis | 10 | $196 |
| Novo Nordisk | 12 | $192 |
| Boehringer Ingelheim | 8 | $179 |
| Sunovion Pharmaceuticals Inc. | 10 | $159 |
| Avanir Pharmaceuticals, Inc. | 7 | $134 |
| Lundbeck LLC | 5 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| UCB, Inc. | 4 | $96 |
| Astellas Pharma US Inc | 3 | $52 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Exact Sciences | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Tactile Systems Technology Inc | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| GSK | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,662 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 678 | $226,804 |
| IngrezzaValbenazine Tosylate | 37 | $147,321 |
| OzempicSemaglutide | 46 | $64,610 |
| FarxigaDapagliflozin Propanediol | 113 | $56,284 |
| JardianceEmpagliflozin | 55 | $46,704 |
| JanuviaSitagliptin Phosphate | 123 | $42,791 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $42,514 |
| MounjaroTirzepatide | 25 | $29,157 |
| LinzessLinaclotide | 44 | $28,945 |
| BelsomraSuvorexant | 77 | $28,669 |
| TrulicityDulaglutide | 31 | $28,122 |
| IsentressRaltegravir Potassium | 25 | $24,649 |
| RexultiBrexpiprazole | 28 | $20,013 |
| XareltoRivaroxaban | 54 | $18,755 |
| RytaryCarbidopa/Levodopa | 26 | $15,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $226,804678 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $23 | $147,32137 claims |
| MerckJanuvia, Belsomra, Isentress | $227 | $96,109225 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Symbicort | $613 | $86,085210 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $179 | $64,94983 claims |
| Novo NordiskOzempic | $192 | $64,61046 claims |
| Lilly USA, LLCMounjaro, Trulicity | $299 | $57,27956 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $17 | $49,99873 claims |
| AbbVieLinzess | $256 | $28,94544 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $230 | $20,01328 claims |
| Johnson & JohnsonXarelto | $17 | $18,75554 claims |
| NovartisEntresto | $196 | $11,80535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Marrero
- Shibu VarugheseMarrero$847K
- Amanda FontenotMarrero$142K
- Alan BowersMarrero$20K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.